Rhabdomyosarcoma is a cancer that develops from immature cells capable of forming skeletal muscle. It can arise almost anywhere in the body, including areas that normally contain little or no skeletal muscle.
It is the most common soft-tissue sarcoma in children. Common sites include the head and neck, tissues around the eye, bladder and reproductive or urinary organs, arms, legs, chest, abdomen, and pelvis.
Rhabdomyosarcoma includes several biological subtypes. Embryonal rhabdomyosarcoma is the most common form in younger children. Alveolar rhabdomyosarcoma more often affects older children and adolescents and is classified partly by whether the tumour has a FOXO1 gene fusion. Spindle-cell and sclerosing tumours include molecularly distinct groups with different patterns of behaviour.
At Apollo Cancer Centres, rhabdomyosarcoma care is planned by a multidisciplinary pediatric sarcoma team that may include pediatric medical oncologists, surgical oncologists, pediatric surgeons, radiation oncologists, radiologists, pathologists, molecular specialists, reconstructive surgeons, and rehabilitation professionals. Treatment is tailored according to tumour site, size, histology, FOXO1 fusion status, lymph-node involvement, surgical group, metastatic spread, and overall risk category.
Risk Factors for Rhabdomyosarcoma
Rhabdomyosarcoma Signs and Symptoms
How Rhabdomyosarcoma Is Diagnosed
Diagnosis begins with a review of the child's symptoms, medical and family history, and previous cancer treatment. The doctor examines the tumour site and assesses nearby lymph nodes, neurological function, movement, vision, hearing, urinary or reproductive structures, and other relevant organs.
Imaging defines the primary tumour, its relationship to nearby structures, lymph-node involvement, and possible metastatic disease. A carefully planned biopsy is required to confirm rhabdomyosarcoma and obtain tissue for molecular testing.
MRI
MRI is generally the preferred test for assessing the primary tumour in the head and neck, limbs, pelvis, genitourinary tract, or paraspinal region. It provides detailed images of muscles, nerves, blood vessels, bone marrow, organs, and other soft tissues. The scan helps determine tumour size, local extent, and whether it can be removed without unacceptable functional or cosmetic harm. It may also show extension through the skull base, into the spinal canal, or along nerve pathways. MRI of the brain may be required for parameningeal tumours close to the skull base or cranial nerves. Sedation or anesthesia may be needed for younger children.
CT Scan
CT may be used to evaluate tumours in the chest, abdomen, pelvis, head, neck, or other anatomically complex regions. It can demonstrate bone involvement, calcification, lung disease, and relationships to major organs or blood vessels. A CT scan of the chest is an important part of staging because the lungs are a recognised site of metastatic spread. Small lung nodules require specialist interpretation because not every nodule is cancerous. CT may also assist biopsy or surgical planning. Pediatric protocols are used to minimise radiation exposure.
Ultrasound
Ultrasound may be the first imaging test for a superficial, abdominal, pelvic, bladder, vaginal, paratesticular, or limb mass. It can distinguish a solid tumour from a fluid-filled lesion and assess blood flow. Doppler ultrasound may show the tumour's relationship to nearby blood vessels. It can also guide a core needle biopsy when the mass is safely accessible. Ultrasound does not replace MRI or CT for complete local staging but can provide useful initial and follow-up information without ionising radiation.
PET-CT
FDG PET-CT may be used to assess the primary tumour, regional lymph nodes, bones, bone marrow, and distant soft-tissue disease. It can help identify an appropriate biopsy site and provide a baseline for response assessment. PET-CT may detect disease not clearly visible on conventional imaging. However, infection, inflammation, and normal childhood tissues can also show increased tracer uptake. PET-CT findings are interpreted alongside MRI, CT, pathology, bone-marrow assessment, and the child's clinical condition.
Bone Scan
A bone scan may be used to identify possible skeletal metastases, particularly when PET-CT is unavailable or further clarification is needed. It detects areas of increased activity throughout the skeleton. Abnormal uptake is not specific to cancer and may also occur with infection, inflammation, trauma, or normal growth. Additional X-ray, MRI, CT, or biopsy may therefore be required. The exact role of bone scanning depends on the treatment protocol and other available staging investigations.
Core Needle Biopsy
Image-guided core needle biopsy is commonly used to diagnose rhabdomyosarcoma. A hollow needle collects several tissue samples under ultrasound, CT, or MRI guidance. The biopsy pathway must be planned with the surgeon who may later remove the tumour. The tract should pass through tissue that can be included in the definitive operation. Adequate samples are required for histopathology, immunohistochemistry, FOXO1 fusion testing, and other molecular studies. Fine-needle aspiration alone may not provide enough tissue for complete classification.
Incisional Biopsy
An incisional biopsy removes a small portion of the tumour through a surgical opening. It may be used when core biopsy is unsafe, technically difficult, or has not provided sufficient tissue. The incision should be placed so that the biopsy tract and scar can be removed during later surgery. Care is taken to avoid contaminating additional tissue compartments. Incisional biopsy may be particularly useful for a large or deeply situated tumour when immediate complete removal would be unsafe or functionally damaging.
Excisional Biopsy
Excisional biopsy removes the entire tumour and may be appropriate for a small, superficial mass that can be removed with an adequate margin without significant functional or cosmetic harm. Unplanned removal of a suspected sarcoma can leave residual disease, contaminate surrounding tissues, and complicate definitive treatment. Imaging and specialist surgical planning should therefore occur before excision whenever rhabdomyosarcoma is possible. The specimen must be oriented and assessed for surgical margins.
Lymph-Node Biopsy
Regional lymph nodes are evaluated clinically and through imaging. Suspicious nodes may be sampled using image-guided core biopsy, surgical excision, or another appropriate technique. Regional lymph-node evaluation is particularly important for alveolar or FOXO1 fusion-positive tumours and tumours arising in limbs or paratesticular sites. Sentinel lymph-node biopsy may be considered for selected extremity tumours. Confirmation of lymph-node involvement affects stage, risk classification, radiation fields, and systemic treatment.
Bone-Marrow and Cerebrospinal Fluid Assessment
Bone-marrow aspiration and biopsy may be performed when metastatic disease is suspected or when the tumour has higher-risk clinical or molecular features. Samples are generally obtained from both sides of the pelvis. Lumbar puncture may be considered for selected parameningeal tumours with skull-base erosion, intracranial extension, or cranial-nerve involvement. It is not routinely required for every child. These investigations are selected according to tumour site, histology, FOXO1 status, imaging, and treatment protocol.
Laboratory
The tissue collected during biopsy or surgery may undergo:
Histopathology: Confirms rhabdomyosarcoma and evaluates the tumour's cellular pattern, differentiation, and areas of necrosis.
Histological classification: Distinguishes embryonal, alveolar, spindle-cell/sclerosing, and other recognised patterns.
Immunohistochemistry: Desmin, myogenin, MyoD1, and other markers help confirm skeletal-muscle differentiation and distinguish rhabdomyosarcoma from other small round-cell tumours.
FOXO1 fusion testing: Identifies PAX3::FOXO1 or PAX7::FOXO1 and is central to the classification and risk assessment of alveolar-pattern tumours.
MYOD1 testing: A MYOD1 alteration defines a clinically important group of spindle-cell or sclerosing rhabdomyosarcomas that may behave aggressively.
VGLL2- or NCOA2-related testing: These alterations may occur in selected infantile spindle-cell rhabdomyosarcomas and can be associated with a more favourable course.
TP53 testing: Tumour or germline testing may be considered when the child's age, history, or tumour findings suggest Li–Fraumeni syndrome.
Broader molecular profiling: This may help clarify an unusual diagnosis or identify potential clinical-trial options in recurrent or refractory disease.
Margin assessment: Surgically removed tissue is examined to determine whether tumour cells reach the edge of the specimen.
Lymph-node assessment: Removed or biopsied nodes are examined for metastatic tumour.
Blood tests may include a complete blood count, kidney and liver function tests, electrolytes, and lactate dehydrogenase. These tests assess the child's general health and treatment readiness but cannot independently diagnose rhabdomyosarcoma.
Genetic counselling may be recommended when the child is very young, has multiple tumours, has an unusual molecular finding, or has physical features or a family history suggesting an inherited cancer-predisposition syndrome.
Rhabdomyosarcoma treatment is planned using a combination of pretreatment stage, clinical group, histological and molecular features, and overall risk category. Stage alone does not provide enough information to select treatment.
Pretreatment Stage
Pretreatment stage considers where the tumour began, tumour size, regional lymph-node involvement, invasion of nearby structures, and distant metastases.
Stage 1: A non-metastatic tumour arising in a favourable site, regardless of tumour size or regional lymph-node involvement. Favourable sites include the orbit, selected non-parameningeal head-and-neck sites, genitourinary sites other than the bladder or prostate, and the biliary tract.
Stage 2: A non-metastatic tumour arising in an unfavourable site that is 5 centimetres or smaller and has not spread to regional lymph nodes.
Stage 3: A non-metastatic tumour arising in an unfavourable site that is larger than 5 centimetres and/or has spread to regional lymph nodes.
Stage 4: The cancer has spread to a distant site at diagnosis.
Tumours in favourable sites have historically had better outcomes or may be easier to control locally. Treatment still considers the complete clinical and biological picture.
Clinical Group
Clinical group describes the amount of tumour remaining after the initial biopsy or surgery:
Group I: The tumour was completely removed with clear margins, and regional lymph nodes do not contain cancer.
Group II: No visible tumour remains, but microscopic tumour is present at a surgical margin and/or regional lymph nodes are involved and have been removed.
Group III: Visible tumour remains after biopsy or incomplete surgery.
Group IV: The cancer had spread to distant parts of the body when diagnosed.
Clinical group does not represent a sequence through which the cancer necessarily progresses. It records the extent of disease remaining after the initial surgical procedure.
How Rhabdomyosarcoma Is Treated
Wide Local Excision
Wide local excision removes the tumour together with a planned margin of surrounding normal tissue. It may be used when complete removal can be achieved without major functional or cosmetic loss. The surgical specimen is examined to assess margins and treatment response. A clear margin reduces the amount of residual local disease but does not remove the need for chemotherapy. Complete removal at diagnosis is not appropriate when the tumour surrounds essential nerves, blood vessels, organs, or structures important for growth and function.
Initial Biopsy
For many tumours, the safest initial operation is a biopsy rather than complete removal. This is particularly true for orbital, parameningeal, bladder, prostate, vaginal, pelvic, or other anatomically complex tumours. Chemotherapy, with or without radiation, is then used to shrink and control the tumour. Definitive surgery may be considered later if it can improve local control without unacceptable harm. Avoiding an overly aggressive initial operation can help preserve vision, continence, fertility, speech, swallowing, and other functions.
Delayed Primary Excision
Delayed primary excision may be considered after several cycles of chemotherapy have reduced the tumour's size. It can help achieve local control and may influence the radiation dose or target in selected protocols. The decision depends on tumour response, location, expected surgical margins, and the functional consequences of the procedure. Surgery should not delay scheduled chemotherapy or radiation unnecessarily. The operation may remove the residual tumour while preserving nearby structures that could not have been safely protected at diagnosis.
Site-Specific Surgery
Surgery is adapted to the part of the body affected. Limb tumours may require wide excision with reconstruction, while genitourinary tumours may require bladder-, vaginal-, uterine-, testicular-, or fertility-preserving approaches. Orbital and parameningeal tumours are rarely treated with extensive initial surgery because of the risk to vision, cranial nerves, facial structures, and the skull base. Biopsy followed by chemotherapy and radiation is commonly used. Head-and-neck, chest, abdominal, and pelvic operations may require collaboration among pediatric, ENT, urological, orthopedic, vascular, and reconstructive surgeons.
Lymph-Node Surgery
Suspicious regional lymph nodes should be sampled or removed to establish whether cancer is present. Accurate nodal assessment is particularly important for extremity, paratesticular, and FOXO1 fusion-positive tumours. Sentinel lymph-node biopsy may help identify microscopic lymphatic spread in selected limb tumours. A negative imaging study does not always exclude small nodal deposits. The results influence stage, risk group, radiation fields, and chemotherapy planning.
Metastatic-Site Surgery
Surgery to remove lung or other metastases is not routinely required for every child because chemotherapy and radiation treat disease throughout the body. It may be considered for a persistent or isolated lesion when complete removal is feasible, when tissue is needed to confirm active disease, or when the finding will change treatment. The decision depends on the primary site, number and location of metastases, response to systemic therapy, and overall risk.
Chemotherapy
Chemotherapy is required for nearly all children with rhabdomyosarcoma because microscopic disease may be present even when the tumour appears localised. Common regimens may include vincristine, dactinomycin, and cyclophosphamide or ifosfamide. Other medicines such as irinotecan, doxorubicin, etoposide, or temozolomide may be used according to risk group, protocol, or disease status. Treatment intensity and duration vary substantially between low-, intermediate-, and high-risk disease. Blood counts, kidney and liver function, heart function, fertility risk, and infection are monitored throughout treatment.
Maintenance Chemotherapy
Some treatment protocols include lower-intensity maintenance chemotherapy after the main chemotherapy programme. Its purpose is to reduce the risk that residual cancer cells will begin growing again. Maintenance may use medicines such as vinorelbine and low-dose cyclophosphamide in protocol-defined schedules. Its use depends on the risk group and treatment approach being followed. The child continues to require blood-count monitoring, infection precautions, and assessment for medicine-related effects.
Relapsed or Refractory Treatment
Treatment for rhabdomyosarcoma that returns or does not respond adequately is individualised. Options may include different chemotherapy combinations, surgery, radiation, targeted therapy, or a clinical trial. The approach depends on the original tumour site, FOXO1 fusion status, time to recurrence, location and number of recurrent sites, previous treatment, and whether all visible disease can be controlled locally. Repeat biopsy and molecular profiling may be considered because the diagnosis or molecular findings can influence available treatment options.
Targeted Therapy
Targeted therapy is not part of standard initial treatment for most rhabdomyosarcomas. Molecular profiling may identify an uncommon alteration that can be treated with a targeted medicine in selected recurrent or refractory cases. Medicines affecting growth-factor, cell-cycle, or other signalling pathways are being evaluated in clinical trials. Their role depends on tumour biology and available clinical evidence. Targeted treatment should be considered through a specialist pediatric molecular tumour board and does not replace established chemotherapy and local control.
External Beam Radiation Therapy
Radiation is an important part of local control for many children with rhabdomyosarcoma. It may be used for visible residual tumour, microscopic residual disease, involved lymph nodes, or tumours in which surgery would cause unacceptable functional or cosmetic harm. The dose and treatment area depend on the tumour site, clinical group, histology, FOXO1 status, response to chemotherapy, and age. Radiation is usually coordinated with chemotherapy at a protocol-defined time. Radiation may occasionally be omitted for selected completely removed, low-risk tumours. Most group III tumours require radiation for durable local control.
Intensity-Modulated Radiation Therapy
IMRT shapes the radiation dose closely around the tumour while limiting exposure to nearby healthy tissues. It may be particularly useful for head-and-neck, orbital, pelvic, bladder, prostate, paraspinal, or other complex tumours. Image guidance verifies positioning during each treatment. Young children may require sedation or anesthesia to remain still. Planning aims to protect vision, hearing, salivary glands, brain, spinal cord, bowel, bladder, reproductive organs, and growing bones where possible.
Proton Therapy
Proton therapy may be considered for selected children when reducing radiation exposure to healthy tissues provides a meaningful advantage. It may be especially relevant for tumours near the brain, skull base, spinal cord, heart, lungs, kidneys, pelvic organs, or growing bones. Protons can reduce the exit dose beyond the tumour compared with some photon-radiation plans. This may help reduce selected long-term effects, although it does not remove all risks of radiation. For appropriate patients, Apollo Proton Cancer Centre can compare proton and advanced photon-radiation plans. Proton therapy is recommended when it provides a clinically meaningful treatment advantage.
Brachytherapy
Brachytherapy places a radiation source within or very close to the tumour site. It may be used for selected bladder, prostate, vaginal, uterine, head-and-neck, or other localised tumours in specialised centres. This approach can deliver a high dose to the target while reducing exposure to surrounding organs. It may be combined with surgery and chemotherapy. Suitability depends on tumour size, site, response to chemotherapy, anatomy, age, and available expertise.
Metastatic-Site Radiation
Radiation may be directed to lung, bone, lymph-node, brain, or other metastatic sites according to the treatment protocol and response to chemotherapy. Whole-lung radiation may be considered for selected children with pulmonary metastases. Focal radiation may relieve pain, protect neurological function, or control persistent metastatic deposits. Treatment is planned within the overall systemic and local-control programme and accounts for previous radiation and nearby growing tissues.
The outlook for rhabdomyosarcoma varies according to the tumour's site, stage, clinical group, molecular features, and response to treatment. Many children with localised, favourable-risk disease can be treated successfully, while metastatic or recurrent disease is more difficult to control.
FOXO1 fusion status is an important prognostic factor, particularly for tumours with alveolar histology. Localised fusion-negative disease generally has a more favourable outlook than fusion-positive or metastatic disease.
Regular follow-up is required because rhabdomyosarcoma can return at the original site or elsewhere in the body. Surveillance may include physical examination, imaging of the primary site, chest imaging, and assessment of treatment-related effects.
Why Choose ACC for Rhabdomyosarcoma Treatment